News
Novo Nordisk's U.S. stock pre-market surged nearly 7%. In terms of news, the company's weight loss drug oral Wegovy's Phase III clinical trial achieved positive results, with patients averaging a weight loss of 16.6%
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments